NASHVILLE, Tenn. (WSMV) - A bill requiring state-run insurance plans to pay for biomarker testing passed committee in an 8-1 vote today at the Tennessee Capitol, moving one step closer to becoming law ...

Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of 26,000 patients showed. Overall, 35% of patients' records had evidence of ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

It’s common to wait until something feels “off” before making an appointment to see a healthcare provider. But waiting for noticeable symptoms can mean missing the chance to catch health issues early.

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting practices, labs, and biopharma for improved patient outcomes. PCC focuses on ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...

We tried out one of the most advanced baseline diagnostic panels available – here’s what we discovered about our health with this biomarker testing… Preventative healthcare has long been the preserve ...

Three years ago, New York state took a huge step forward by expanding access to biomarker testing, which is said to be a game changer in cancer care. Now, however, advocates fear the state could be ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...